Revvity, Inc. (NYSE:RVTY) Shares Bought by CANADA LIFE ASSURANCE Co

CANADA LIFE ASSURANCE Co grew its stake in shares of Revvity, Inc. (NYSE:RVTY - Free Report) by 18.5% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 86,081 shares of the company's stock after purchasing an additional 13,428 shares during the quarter. CANADA LIFE ASSURANCE Co owned approximately 0.07% of Revvity worth $9,606,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also modified their holdings of RVTY. Victory Capital Management Inc. lifted its stake in Revvity by 17.4% in the fourth quarter. Victory Capital Management Inc. now owns 70,250 shares of the company's stock valued at $7,841,000 after buying an additional 10,390 shares during the last quarter. JPMorgan Chase & Co. raised its position in Revvity by 13.7% in the 3rd quarter. JPMorgan Chase & Co. now owns 344,115 shares of the company's stock valued at $43,961,000 after purchasing an additional 41,497 shares during the last quarter. Contravisory Investment Management Inc. boosted its stake in Revvity by 1,715.9% during the 4th quarter. Contravisory Investment Management Inc. now owns 69,186 shares of the company's stock worth $7,722,000 after purchasing an additional 65,376 shares during the period. Janney Montgomery Scott LLC grew its position in Revvity by 87.0% during the 4th quarter. Janney Montgomery Scott LLC now owns 7,891 shares of the company's stock worth $881,000 after purchasing an additional 3,672 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. increased its stake in Revvity by 41.5% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 12,072 shares of the company's stock valued at $1,352,000 after purchasing an additional 3,542 shares during the period. Hedge funds and other institutional investors own 86.65% of the company's stock.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on RVTY shares. KeyCorp raised their price target on Revvity from $132.00 to $145.00 and gave the stock an "overweight" rating in a report on Monday, February 3rd. Robert W. Baird cut their price target on Revvity from $141.00 to $127.00 and set an "outperform" rating for the company in a research note on Monday. Raymond James reaffirmed an "outperform" rating and set a $145.00 price target (up from $140.00) on shares of Revvity in a report on Monday, February 3rd. Sanford C. Bernstein cut shares of Revvity from an "outperform" rating to a "market perform" rating and set a $130.00 price objective on the stock. in a research note on Friday, January 10th. Finally, Barclays lowered their price objective on Revvity from $140.00 to $110.00 and set an "overweight" rating on the stock in a report on Thursday, April 10th. Four equities research analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $130.50.

Insider Activity at Revvity

In related news, insider Joel S. Goldberg sold 15,170 shares of the stock in a transaction dated Thursday, January 30th. The stock was sold at an average price of $126.73, for a total transaction of $1,922,494.10. Following the transaction, the insider now directly owns 33,400 shares in the company, valued at approximately $4,232,782. This represents a 31.23 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Insiders own 0.68% of the company's stock.

Revvity Price Performance

Shares of Revvity stock traded down $0.83 during trading on Friday, hitting $94.30. 1,390,004 shares of the company were exchanged, compared to its average volume of 912,016. The firm has a 50 day moving average price of $105.22 and a 200 day moving average price of $113.28. The stock has a market capitalization of $11.33 billion, a price-to-earnings ratio of 42.67, a P/E/G ratio of 3.82 and a beta of 1.07. The company has a quick ratio of 3.03, a current ratio of 3.60 and a debt-to-equity ratio of 0.41. Revvity, Inc. has a fifty-two week low of $88.53 and a fifty-two week high of $129.50.

Revvity (NYSE:RVTY - Get Free Report) last issued its quarterly earnings data on Friday, January 31st. The company reported $1.42 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.37 by $0.05. Revvity had a return on equity of 7.68% and a net margin of 9.81%. During the same period in the prior year, the company earned $1.25 EPS. On average, equities analysts expect that Revvity, Inc. will post 4.94 earnings per share for the current fiscal year.

Revvity Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, August 8th. Stockholders of record on Friday, July 18th will be given a $0.07 dividend. This represents a $0.28 dividend on an annualized basis and a dividend yield of 0.30%. The ex-dividend date is Friday, July 18th. Revvity's dividend payout ratio is presently 12.67%.

About Revvity

Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.